Therefore, in the present study, eight-month-old APP/PS1 mice were utilized to assess whether B9M could alleviate the learning and memory deficits and Aβ aggregation of AD with the aim of evaluating the potential of B9M for the treatment of AD. The gene discussed is APP; the disease is Alzheimer disease.